Stock MED MEDIFAST, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Medifast, Inc.

Equities

MED

US58470H1014

Food Processing

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-26 pm EDT 		5-day change 1st Jan Change
33.71 USD +0.63% Intraday chart for Medifast, Inc. +3.91% -49.85%
Feb. 20 Medifast, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Feb. 20 Transcript : Medifast, Inc., Q4 2023 Earnings Call, Feb 20, 2024

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 1,267 2,301 2,424 1,253 724.4 363.4 -
Enterprise Value (EV) 1 1,175 2,126 2,314 1,166 630 181 129.7
P/E ratio 17 x 22.6 x 15.1 x 9.06 x 7.39 x 17.7 x 10.8 x
Yield - 2.3% 2.71% - - - -
Capitalization / Revenue 1.78 x 2.46 x 1.59 x 0.78 x 0.68 x 0.52 x 0.48 x
EV / Revenue 1.65 x 2.27 x 1.52 x 0.73 x 0.59 x 0.26 x 0.17 x
EV / EBITDA 12.3 x 14.3 x 10.4 x 5.14 x 4.28 x 4.11 x 2.11 x
EV / FCF 15.8 x 15.3 x 38.4 x 6.55 x - 4.61 x 2.58 x
FCF Yield 6.32% 6.55% 2.61% 15.3% - 21.7% 38.8%
Price to Book - - - - - - -
Nbr of stocks (in thousands) 11,564 11,718 11,574 10,865 10,777 10,782 -
Reference price 2 109.6 196.3 209.4 115.4 67.22 33.71 33.71
Announcement Date 2/26/20 2/25/21 2/23/22 2/21/23 2/20/24 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net sales 1 713.7 934.8 1,526 1,599 1,072 694.4 755.8
EBITDA 1 95.66 148.5 223.1 227 147.1 44.05 61.5
EBIT 1 91.04 141.2 216.2 216 134 23.05 39.9
Operating Margin 12.76% 15.1% 14.17% 13.51% 12.5% 3.32% 5.28%
Earnings before Tax (EBT) 1 92.36 134.3 216.1 184.1 128.8 27.05 44.5
Net income 1 77.92 102.9 164 143.6 99.42 20.85 34.3
Net margin 10.92% 11% 10.75% 8.98% 9.27% 3% 4.54%
EPS 2 6.430 8.680 13.89 12.73 9.100 1.905 3.135
Free Cash Flow 1 74.2 139.3 60.34 177.9 - 39.25 50.3
FCF margin 10.4% 14.9% 3.95% 11.13% - 5.65% 6.66%
FCF Conversion (EBITDA) 77.57% 93.83% 27.05% 78.38% - 89.1% 81.79%
FCF Conversion (Net income) 95.23% 135.44% 36.78% 123.91% - 188.25% 146.65%
Dividend per Share - 4.520 5.680 - - - -
Announcement Date 2/26/20 2/25/21 2/23/22 2/21/23 2/20/24 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 413.4 377.8 417.6 453.3 390.4 337.2 349 296.2 235.9 191 168.9 175.1 176 174.4 177.4
EBITDA 1 57.81 46.37 57.53 61.12 52.09 56.22 64.49 42.07 28.92 19.58 13.8 14.3 9.45 6.45 13.85
EBIT 1 55.17 46.84 55.09 58.39 49.24 53.27 53.51 38.71 25.51 16.23 10.25 8.5 3.55 0.75 10.15
Operating Margin 13.35% 12.4% 13.19% 12.88% 12.61% 15.79% 15.33% 13.07% 10.81% 8.5% 6.07% 4.85% 2.02% 0.43% 5.72%
Earnings before Tax (EBT) 1 55.19 46.75 54.98 48.8 47.88 32.41 53.33 39.12 26.55 9.802 11.1 9.5 4.65 1.8 11.15
Net income 1 41.98 34.02 41.78 39.11 36.16 26.52 39.97 30.28 23.13 6.036 8.55 7.3 3.55 1.4 8.6
Net margin 10.16% 9% 10.01% 8.63% 9.26% 7.86% 11.45% 10.22% 9.81% 3.16% 5.06% 4.17% 2.02% 0.8% 4.85%
EPS 2 3.560 2.910 3.590 3.420 3.270 2.410 3.670 2.770 2.120 0.5500 0.7800 0.6650 0.3250 0.1300 0.7900
Dividend per Share 1.420 1.420 1.640 - - - - 1.650 1.650 - - - - - -
Announcement Date 11/4/21 2/23/22 5/2/22 8/3/22 11/3/22 2/21/23 5/1/23 8/7/23 11/6/23 2/20/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 - - - - - - -
Net Cash position 1 92.7 174 110 87.7 94.4 182 234
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 1 74.2 139 60.3 178 - 39.3 50.3
ROE (net income / shareholders' equity) 72.8% 78.5% 91.2% 80.3% 59% 9.6% 16.5%
ROA (Net income/ Total Assets) - - 48.6% - - - -
Assets 1 - - 337.2 - - - -
Book Value Per Share - - - - - - -
Cash Flow per Share - - - - - - -
Capex 1 10.1 5.89 34.2 16.7 - 9.9 11.2
Capex / Sales 1.41% 0.63% 2.24% 1.04% - 1.43% 1.48%
Announcement Date 2/26/20 2/25/21 2/23/22 2/21/23 2/20/24 - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Medifast, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
33.71 USD
Average target price
37.5 USD
Spread / Average Target
+11.24%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Special Foods & Wellbeing Products

1st Jan change Capi.
MEDIFAST, INC. Stock Medifast, Inc.
-49.85% 363M
ZHEJIANG NHU COMPANY LTD. Stock Zhejiang NHU Company Ltd.
+8.20% 7.78B
BELLRING BRANDS, INC. Stock BellRing Brands, Inc.
+0.34% 7.38B
CSPC INNOVATION PHARMACEUTICAL CO., LTD. Stock CSPC Innovation Pharmaceutical Co., Ltd.
+10.20% 6.52B
BYHEALTH CO., LTD Stock Byhealth Co., Ltd
-8.10% 3.67B
THE SIMPLY GOOD FOODS COMPANY Stock The Simply Good Foods Company
-13.13% 3.44B
XIAMEN KINGDOMWAY GROUP COMPANY Stock Xiamen Kingdomway Group Company
-14.57% 1.17B
SIRIO PHARMA CO., LTD. Stock Sirio Pharma Co., Ltd.
+8.34% 934M
HERBALIFE LTD. Stock Herbalife Ltd.
-42.27% 879M
USANA HEALTH SCIENCES, INC. Stock USANA Health Sciences, Inc.
-18.90% 836M
Special Foods & Wellbeing Products
  1. Stock Market
  2. Equities
  3. MED Stock
  4. Financials Medifast, Inc.